After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
NAMS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of NewAmsterdam Pharma Company NV is $3.94B. A total of 0.74 million shares were traded on the day, compared to an average of 1.12M shares.
In the most recent transaction, Kooij Louise Frederika sold 75,117 shares of NAMS for 36.21 per share on Dec 23 ’25. After the transaction, the Chief Accounting Officer now owns 15,000 company shares. In a previous transaction on Dec 26 ’25, Kooij Louise Frederika sold 43,872 shares at 35.30 per share. NAMS shares that Chief Accounting Officer owns now total 15,000.
Among the insiders who sold shares, Kooij Louise Frederika disposed of 26,011 shares on Dec 24 ’25 at a per-share price of $35.68. This resulted in the Chief Accounting Officer holding 15,000 shares of NAMS after the transaction. In another insider transaction, Louise Kooij bought 290,000 shares at $36.49 per share on Dec 23 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, NAMS has a high of $42.00 and a low of $14.06.
As of this writing, NAMS has an earnings estimate of -$0.37 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$0.09 per share and a lower estimate of -$0.53. The company reported an EPS of -$0.9 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. NAMS’s latest balance sheet shows that the firm has $60.11M in Cash & Short Term Investments as of fiscal 2021. There were $185.68k in debt and $11.19M in liabilities at the time. Its Book Value Per Share was $6.43, while its Total Shareholder’s Equity was $56.37M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NAMS is Buy with a score of 4.60.
